Diabetes

Many hoped the 2013 declaration by the American Medical Association that obesity is a disease would open the door for payer coverage of pharmacotherapy to treat it. While that did not happen right way, a new commentary in Evidence-Based Diabetes Management by Ted Kyle, RPh, MBA, and Fatima Cody Stanford, MD, MPH, MPA, outlines how the tide appears to be turning for coverage of evidence-based treatment.

Peter S. Amenta, MD, PhD, spent 8 years as the dean of Rutgers Robert Wood Johnson Medical School during a period of tremendous growth and change.

The research by the group from Spain is the latest effort to link sleep patterns, or disruption of sleep, to the development of type 2 diabetes.

Fingernail tests could offer a solution to diabetes testing in the developing world, and a faster test for gestational diabetes could diagnose this condition earlier in pregnancy.

A JAMA Internal Medicine study found the terms "breakthrough" and "promising" raised people's expectations on the drug's performance as opposed to when the drugs were described as having met the breakthrough criteria.

Younger patients and those newly diagnosed were more likely to not receive eye exams than older persons with diabetes.

Screening in a primary care setting may help managed care plans avoid long-term costs of complications of type 2 diabetes.

Hillary Clinton unveiled a plan in Iowa that features a $250 per month cap on drug costs for patients with chronic conditions. This comes 2 weeks after her chief rival for the Democratic nomination, US Senator Bernie Sanders of Vermont, introduced a bill aimed at reining in drug costs. In the summer, The American Journal of Managed Care said polling showed that rising drug costs were poised to become a major issue in the 2016 campaign.

A white paper released by QuantiaMD has identified a lack of awareness and education about biosimilars among prescribing physicians.

The matchstick-like delivery system has been seen as game-changer in overcoming poor adherence. Filing for FDA approval is anticipated in early 2016.

The study showed an average weight loss of 6%, and weight loss of 10% for a quarter of the patients. Average BMI was 37.

The research could hold the key to a novel treatment for type 2 diabetes, although it will take years to adapt the idea to clinical practice.

Researcher found that not only was passive smoking associated with increased risk of type 2 diabete, but there was a direct dose-response relationship.

A report in The New York Times identifies challenges that could be raised based on Califf's past associations with the drug industry.

Although primary care is important, it may not be the center of the care model for patients with chronic diseases, like type 2 diabetes, and these providers are usually just a part of a larger ecosystem of providers, said Andrew Pumerantz, DO, FACP.

Researchers are proposing a new model to integrate clinical and community services for the purpose of preventing and controlling obesity, as well as related chronic diseases, such as type 2 diabetes.

Many hoped the 2013 declaration by the American Medical Association that obesity is a disease would open the door to improved coverage for pharmcotherapy. That did not happen right away, but signs of change are emerging.

A 5-year study reveals that the properly constructed diet, along with exercise aimed at muscle maintenance, can achieve long-term weight loss results.

Patients whose blood sugar and insulin delivery was managed by software had been control than those who had to self-monitor their insulin delivery.

The path to President Obama's Precision Medicine Initiative has been paved as is evident from a report released by a Working Group convened by the National Institutes of Health.

Work at the Karolinska Institutet has revealed a potential new therapeutic target in type 2 diabetes.

The long-term claimed to be the first to use real world data to capture the complete picture of the value of paying for bariatric surgery in patients with diabetes.

Presentation of results at the European Association for the Study of Diabetes follows the announcement of topline results in August. For years, researchers and pharmaceutical leaders alike wondered if a diabetes therapy would be shown to have a cardioprotective effect.

Evidence-Based Diabetes Management gained exclusive access to the Comprehensive Weight Management Program for a view of what "behavioral change" really means for patients overcoming obesity and for the clinicians managing their care.

The company's Prevent program is approved by CDC as meeting standards for obesity prevention counseling as required of payers by the US Prevention Services Task Force.

Many more patient than provider characteristics are associated with optimal or poor glycemic control and treatment intensification when glycemic control is initially lost.

Researchers analyzed patient records from a 25-year period and found risks increased with higher doses and longer periods of treatment.

Regulatory filings with the FDA are expected before the end of the year.